VANDETANIB, DESIGNED TO INHBIT VEGFR2 AND EGFR SIGNALLING, HAD NO CLINICAL ACTIVITY AS MONOTHERAPY FOR RECURRENT OVARIAN CANCER AND NO DETECTABLE MODULATION OF VEGFR2

PURPOSE: To evaluate clinical activity and target modulation of vandetanib in women with recurrent ovarian cancer. EXPERIMENTAL DESIGN: A phase II trial of orally administered vandetanib 300mg daily was designed to include analyses of target inhibition through paired biopsies and dynamic imaging. Co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Annunziata, Christina M., Walker, Amanda J., Minasian, Lori, Yu, Minshu, Kotz, Herbert, Wood, Bradford J., Calvo, Katherine, Choyke, Peter, Kimm, Daniel, Steinberg, Seth, Kohn, Elise C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2943831/
https://ncbi.nlm.nih.gov/pubmed/20068097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-2308
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados